Trial Profile
Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 24 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 02 Sep 2022 Planned End Date changed from 1 Aug 2022 to 1 Jan 2023.
- 02 Sep 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Jan 2023.